EUVIMEDEUVIMED entdecken
Crossref

Exploring the neuroprotective potential of trigonelline as a multitarget therapeutic candidate for Alzheimer’s disease: network pharmacology, molecular docking, molecular dynamics, DFT analysis and in vitro studies

Shailaja Nare, Kiran Gaikwad, Sukanya Pote, Deepa Mandlik

Journal of Molecular Modeling · 2026-11 · 32 (11)

DOI: 10.1007/s00894-026-07024-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Modeling, online erschienen am 03.11.2026. Verfasst von Shailaja Nare und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Erandwane, Pune, 411038, Maharashtra, India. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Alzheimer Disease, Neuroprotective Agents, Alkaloids. Die Arbeit nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CONTEXT: Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by cholinergic dysfunction, oxidative stress, neuroinflammation, synaptic impairment, and progressive neuronal loss. Trigonelline (TGN), a naturally occurring pyridinium alkaloid, has shown neuroprotective potential, although its molecular mechanisms in AD remain incompletely understood. This study investigated the multitarget therapeutic potential of TGN through an integrated computational and experimental validation. METHODS: Network pharmacology identified 78 common targets between TGN and AD, with ACHE, CHRM1, CHRM2, CHRNA3, CHRNA4, CHRNB2, CHRNB4, GABRA1, GABRB2, and GABRG2 as hub genes. Functional enrichment revealed significant involvement of neuroactive ligand-receptor interaction, cholinergic synapse, PI3K-Akt, MAPK, calcium, apoptosis, and TNF signaling pathways. Docking analysis predicted favorable interactions of TGN with acetylcholinesterase (AChE; PDB ID: 4EY6; - 7.907 kcal/mol) and the M2 muscarinic receptor (PDB ID: 5ZK8; - 8.404 kcal/mol), with docking scores in a similar computational range to those obtained for donepezil. A 500-ns molecular dynamics simulation, supported by principal component analysis, dynamic cross-correlation matrix analysis, free energy landscape, and density functional theories analyses, confirmed stable protein-ligand interactions. Experimental validation in TMT-induced SH-SY5Y cells showed that TGN increased cell viability to 116 ± 1% at 80 µM and reduced LDH release to 126.4 ± 1.8% at 40 µM, demonstrating concentration-dependent neuroprotection. These findings provide experimental evidence for the cytoprotective potential of TGN, while the network pharmacology, molecular docking, molecular dynamics, and pathway analyses provide computationally predicted molecular mechanisms involving cholinergic signaling and neuronal survival, stress-response, and inflammatory pathways. Importantly, the predicted target interactions and pathway involvement were not directly validated experimentally in the present study. Further target-specific and pathway-level investigations are required to establish the precise mechanism of action of TGN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationAlzheimer DiseaseNeuroprotective AgentsAlkaloidsMolecular Dynamics SimulationHumansAcetylcholinesteraseNetwork PharmacologyReceptor, Muscarinic M2Signal Transduction

Stichwörter der Autor:innen

Alzheimer’s diseaseDensity functional theoryMolecular dockingMolecular dynamicsNetwork pharmacologySH-SY5YTrigonelline

Substanzen

Neuroprotective AgentsAlkaloidstrigonellineAcetylcholinesteraseReceptor, Muscarinic M2

Autor:innen und Institutionen

  • Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Erandwane, Pune, 411038, Maharashtra, India.
  • Department of Pharmaceutical Chemistry, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, 590010, Karnataka, India.
  • Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, 415539, Maharashtra, India.
  • Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Erandwane, Pune, 411038, Maharashtra, India. deepa.mandlik@bharatividyapeeth.edu.

Zitieren

APA

Nare, S., Gaikwad, K., Pote, S., & Mandlik, D. (2026). Exploring the neuroprotective potential of trigonelline as a multitarget therapeutic candidate for Alzheimer’s disease: network pharmacology, molecular docking, molecular dynamics, DFT analysis and in vitro studies. Journal of Molecular Modeling, 32(11). https://doi.org/10.1007/s00894-026-07024-8

Vancouver

Nare S, Gaikwad K, Pote S, Mandlik D. Exploring the neuroprotective potential of trigonelline as a multitarget therapeutic candidate for Alzheimer’s disease: network pharmacology, molecular docking, molecular dynamics, DFT analysis and in vitro studies. Journal of Molecular Modeling. 2026;32(11). doi:10.1007/s00894-026-07024-8

BibTeX
@article{Nare2026,
  author = {Nare, Shailaja and Gaikwad, Kiran and Pote, Sukanya and Mandlik, Deepa},
  title = {Exploring the neuroprotective potential of trigonelline as a multitarget therapeutic candidate for Alzheimer’s disease: network pharmacology, molecular docking, molecular dynamics, DFT analysis and in vitro studies},
  journal = {Journal of Molecular Modeling},
  year = {2026},
  volume = {32},
  number = {11},
  doi = {10.1007/s00894-026-07024-8}
}
Kostenlos starten →